Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Latanoprost to Preservative-Free Tafluprost in Glaucoma
NCT00596791Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2008
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tafluprost in ocular hypertension, open-angle glaucoma (OAG), sponsored by Santen Pharmaceutical. Started Jan 2008; status: completed.
02
Drugs
tafluprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00596791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00596791.